News

Article

EMA Grants Orphan Drug Designation to Epidiolex for Treatment of Lennox-Gastaut Syndrome

GW Pharmaceuticals plans to submit a regulatory filing to FDA and EMA following two positive Phase III trials of Epidiolex in patients with Lennox-Gastaut Syndrome.

Biopharmaceutical company, GW Pharmaceuticals announced that the European Medicines Agency (EMA) has granted orphan drug designation to GW’s investigational product Epidiolex (cannabidiol [CBD]) in the treatment of Lennox-Gastaut Syndrome (LGS), a treatment-resistant, debilitating childhood-onset epilepsy.

"Following two positive Phase III trials of Epidiolex in patients with LGS, GW is committed to pursuing registration of Epidiolex in Europe in order to provide these patients access to an approved prescription CBD medicine," Justin Gover, the company’s CEO said in a press statement. According to Gover, GW is preparing to submit a new drug application with FDA in the middle of 2017, and to EMA shortly after that.

GW has also been granted orphan drug designation by EMA for Epidiolex in the treatment of Dravet syndrome. In the US, GW has received orphan drug designation from FDA for Epidiolex in the treatment of LGS, Dravet syndrome, tuberous sclerosis complex (TSC), and infantile spasms, each of which are severe infantile-onset, drug-resistant epilepsy syndromes. FDA has also granted fast-track designation to Epidiolex for the treatment of Dravet syndrome.

Epidiolex is GW’s lead cannabinoid product candidate. It is a proprietary oral solution of pure plant-derived CBD. GW is developing the compound for the treatment of severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, LGS, TSC, and infantile spasms.

Source: GW Pharmaceuticals 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content